Clinical Trials Logo

Acquired Immunodeficiency Syndrome clinical trials

View clinical trials related to Acquired Immunodeficiency Syndrome.

Filter by:

NCT ID: NCT03583138 Completed - Clinical trials for Human Immunodeficiency Virus

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

Start date: June 23, 2014
Phase: Phase 4
Study type: Interventional

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

NCT ID: NCT03577470 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate

Start date: June 13, 2018
Study type: Observational

The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot algorithm through collection of daily practice data in the Italian setting.

NCT ID: NCT03575143 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living With HIV

Start date: August 2, 2018
Study type: Observational

The investigators seek to understand how the different underlying causes of OSA affect the way people living with HIV (PLWH) experience OSA. The investigators also want to understand how symptoms of obstructive sleep apnea improve with treatment, and if this too, is affected by the underlying cause of OSA in that individual

NCT ID: NCT03572335 Not yet recruiting - HIV Infections Clinical Trials

Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)

Start date: July 2018
Study type: Observational

Diffusing capacity for carbon monoxide (DLco) abnormalities are common in HIV+ individuals and associated with significant morbidity and mortality. The complexity and the individualized differences in causes of these abnormalities have been challenging to unravel using traditional approaches. In this proposal, the investigators construct a systems' modeling approach to identify novel molecular and clinical pathways contributing to DLco impairment in HIV+ individuals and to determine predictive signatures of DLco decline in order to develop strategies to treat and prevent abnormal lung function in this susceptible population.

NCT ID: NCT03564613 Active, not recruiting - HIV Infections Clinical Trials

Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

Start date: June 12, 2018
Study type: Observational

The purpose of this study is to assess the safety and effectiveness of DTG use in HIV positive pregnant women. This is a 3-year multi-site prospective observational study. Approximately, 250 HIV positive pregnant women from potential European AIDS Treatment Network (NEAT ID) sites across Europe will be enrolled. The enrollment period will be over 2 years with a follow-up period of 1 year for outcomes. The data collected will be that obtained during routine standard of care assessments; and the subjects will not undergo any interventional study procedures.

NCT ID: NCT03563742 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus Infections

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Start date: July 20, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to evaluate the efficacy of rilpivirine (RPV)-based regimen in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive participants, as determined by the percentage of virologic responders defined as having HIV-1 ribonucleic acid (RNA) less than 400 copies/ milliliter (mL) at Week 24.

NCT ID: NCT03561103 Recruiting - Clinical trials for Human Immunodeficiency Virus

Impact of Representative Payee Services on ART Adherence Among Marginalized People Living With HIV/AIDS

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Client-Centered Representative Payee is a structural intervention that provides financial management support to PLWHA by modifying the implementation of a long-standing policy within the Social Security Administration, in which an organization is authorized to serve as the client's payee. The central hypothesis of this study is that by helping clients to pay rent and other bills on time, housing stability will improve and financial stress will decrease. By reducing the cognitive burden of living with chronic financial stress and frequent threats of housing loss, clients can devote more time and attention to medical appointments and medication adherence. It is further hypothesized that these changes will improve clients' self-efficacy for health behaviors, retention in care, medication adherence, and viral loads. These hypotheses will be tested via the following specific aims: (1) Conduct a randomized controlled trial (n=320) to test the effect of Client-Centered Rep Payee on ART adherence and viral load among PLWHA who are economically disadvantaged and unstably housed. Clinical adherence will be compared through behavioral and biological measures including prescription refill data, self-reported appointment adherence, and viral load for patients receiving the intervention versus those receiving standard of care. (2) Test underlying mechanisms associated with Client-Centered Rep Payee that contribute to changes in medication adherence and viral suppression rates. This will be accomplished via use of quantitative (mediation analysis) and qualitative (semi-structured interview) methods to test hypothesized mediators of medication adherence and viral suppression including financial and housing instability, financial stress, self-efficacy for health behaviors, and retention in care. (3) Assess the cost and cost-effectiveness of the Client-Centered Rep Payee model. An economic analysis will be conducted to model the impact of the intervention as compared with standard of care on quality adjusted life years as well as new infections averted. This approach is innovative because it offers a structural intervention to improve adherence by addressing the effects of economic insecurity, requires low financial investment, and can be layered with existing clinical services. Further, it is highly scalable as it builds on a current policy in practice within the Social Security system.

NCT ID: NCT03558438 Recruiting - HIV Infections Clinical Trials

Spanish Cohort of Patients With HIV Infection Older Than 50 Years for the Study of Fragility and Physical Function

Start date: May 7, 2018
Study type: Observational

It's a prospective observational study to assess frailty and physical function

NCT ID: NCT03554408 Recruiting - Clinical trials for Human Immunodeficiency Virus

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Start date: June 2018
Phase: Phase 1
Study type: Interventional

This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.

NCT ID: NCT03547739 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus

Testing Strategies for Couple Engagement in PMTCT and Family Health in Kenya

Jamii Bora
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This study will test the efficacy and cost-effectiveness of an interdependence theory-based couples intervention in Kenya that reaches pregnant women and male partners through home visits by male-female pairs of lay health workers, and includes offer of home-based CHTC services.